Read + Share
Yamaba S, Imai Y, Sugawara K, Uchida Y, et al. Usefulness of atezolizumab plus bevacizumab as second-line therapy for patients
with unresectable hepatocellular carcinoma. PLoS One 2024;19:e0298770.
PMID: 38687817
|
 |
|
Yamaba S, Imai Y, Sugawara K, Uchida Y, et al. Usefulness of atezolizumab plus bevacizumab as second-line therapy for patients
with unresectable hepatocellular carcinoma. PLoS One 2024;19:e0298770.
PMID: 38687817
|
|
|
|